Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation

References

• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv4. doi:10.1126/scitranslmed.aad7118
   PubMed Web of Science ®Google Scholar
• Ai L, Chen J, Yan H, et al. Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther. 2020;14:3625–3649. doi:10.2147/DDDT.S267433
   PubMed Web of Science ®Google Scholar
• Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92. doi:10.1186/s13045-019-0779-5
   PubMed Web of Science ®Google Scholar
• Yang X, Ma L, Zhang X, et al. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp Hematology Oncol. 2022;11(1):11.
   PubMed Web of Science ®Google Scholar
• Berthon C, Driss V, Liu J, et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother. 2010;59(12):1839–1849. doi:10.1007/s00262-010-0909-y
   PubMed Web of Science ®Google Scholar
• Brodská B, Otevřelová P, Šálek C, et al. High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations. IJMS. 2019;20(11):2823. doi:10.3390/ijms20112823
   Google Scholar
• Zhang Z-F, Zhang Q-T, Xin H-Z, et al. Expression of programmed death ligand-1 (PD-L1) in human acute leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(4):930–934.
   PubMedGoogle Scholar
• Krönig H, Kremmler L, Haller B, et al. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol. 2014;92(3):195–203. doi:10.1111/ejh.12228
   PubMed Web of Science ®Google Scholar
• Williams P, Basu S, Garcia-Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125(9):1470–1481. doi:10.1002/cncr.31896
   PubMed Web of Science ®Google Scholar
• Daver N, Basu S, Garcia-Manero G, et al. Defining the immune checkpoint landscape in patients (pts) with acute myeloid leukemia (AML). Blood. 2016;128(22):2900–2900. doi:10.1182/blood.V128.22.2900.2900
   Web of Science ®Google Scholar
• Tang L, Wu J, Li C-G, et al. Characterization of immune dysfunction and identification of prognostic immune-related risk factors in acute myeloid leukemia. Clin Cancer Res. 2020;26(7):1763–1772. doi:10.1158/1078-0432.CCR-19-3003
   PubMed Web of Science ®Google Scholar
• Ge W, Ma X, Li X, et al. B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of treg cells. Leuk Res. 2009;33(7):948–957. doi:10.1016/j.leukres.2009.01.007
   PubMed Web of Science ®Google Scholar
• Dong Y, Han Y, Huang Y, et al. PD-L1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia. Front Immunol. 2020;11:1710. doi:10.3389/fimmu.2020.01710
   PubMed Web of Science ®Google Scholar
• Dolen Y, Esendagli G. Myeloid leukemia cells with a B7-2+ subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. Eur J Immunol. 2013;43(3):747–757. doi:10.1002/eji.201242814
   PubMed Web of Science ®Google Scholar
• Li P, Huang T, Zou Q, et al. FGFR2 promotes expression of PD-L1 in colorectal cancer via the JAK/STAT3 signaling pathway. J Immunol. 2019;202(10):3065–3075. doi:10.4049/jimmunol.1801199
   PubMed Web of Science ®Google Scholar
• Doi T, Ishikawa T, Okayama T, et al. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol Rep. 2017;37(3):1545–1554. doi:10.3892/or.2017.5399
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–3277. doi:10.1182/blood-2010-05-282780
   PubMed Web of Science ®Google Scholar
• Prestipino A, Emhardt AJ, Aumann K, et al. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018;10(429): eaam7729. doi:10.1126/scitranslmed.aam7729
   PubMed Web of Science ®Google Scholar
• Vicente C, Vázquez I, Marcotegui N, et al. JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers. Leukemia. 2007;21(11):2386–2390. doi:10.1038/sj.leu.2404812
   PubMed Web of Science ®Google Scholar
• Kulangara K, Zhang N, Corigliano E, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–337. doi:10.5858/arpa.2018-0043-OA
   PubMed Web of Science ®Google Scholar
• Emancipator K. Keytruda and PD-L1: a real-world example of co-development of a drug with a predictive ­biomarker. Aaps J. 2020;23(1):5. doi:10.1208/s12248-020-00525-1
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lavu S, Mudireddy M, et al. JAK2 exon 12 mutated polycythemia vera: mayo-careggi MPN alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. Am J Hematol. 2018;93(4):E93–E96. doi:10.1002/ajh.25017
   PubMed Web of Science ®Google Scholar
• Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111(3):1686–1689. doi:10.1182/blood-2007-07-101576
   PubMed Web of Science ®Google Scholar
• Scott LM, Tong W, Levine A, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. Engl J Med. 2007;356(5):459–68. doi:10.1056/NEJMoa065202
   PubMed Web of Science ®Google Scholar
• Giannopoulos K. Targeting immune signaling checkpoints in acute myeloid leukemia. JCM. 2019;8(2):236. doi:10.3390/jcm8020236
   Google Scholar
• Daver N. Immune checkpoint inhibitors in acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34(1):101247. doi:10.1016/j.beha.2021.101247
   PubMed Web of Science ®Google Scholar